Amarin Corp Plc\Uk
$5.60B- Market cap
- $5.73B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: AMRN stock price at premium vs FFIV $13.63 current versus $3.69 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FFIV's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · FFIV FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.21x
Capital structure 98% equity / 2% debt · EV / Revenue 6.86x · EV / EBITDA 24.89x
FFIV carries the larger enterprise value at $21.19B against $5.60B; FFIV trades on the lower EV / Revenue multiple (6.86x vs 26.21x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
F5, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
0.12x
Net debt / EBITDA
Leverage against operating earnings
3.79x
-1.09x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$1.34B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
AKAMAI TECHNOLOGIES INC
AMRN vs AKAM
Fastly, Inc.
AMRN vs FSLY
Palo Alto Networks Inc
AMRN vs PANW
DIGI INTERNATIONAL INC
AMRN vs DGII
JUNIPER NETWORKS INC
AMRN vs JNPR
VERISIGN INC/CA
AMRN vs VRSN
$177.39M
$419.78M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.